October 24, 2023

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-1004

 

  Re: Avenue Therapeutics, Inc.
    Registration Statement on Form S-1, as amended
    File No. 333-274562

 

Ladies and Gentlemen:

 

As the placement agent of the proposed offering of Avenue Therapeutics, Inc. (the “Company”), we hereby join the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 5:30 p.m., Eastern Time, on Wednesday, October 25, 2023, or as soon thereafter as is practicable, or at such other time as may be advised by the Company’s counsel.

 

Pursuant to Rule 460 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, we wish to advise you that, through October 24, 2023, we distributed to each dealer, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies, as well as “E-red” copies of the Preliminary Prospectus dated October 23, 2023, as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

 

The undersigned advise that they have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

 

 

  Very truly yours,  
     
  Maxim Group LLC  
     
  By:  /s/ Clifford A. Teller  
    Name: Clifford A. Teller
Title: Co-President